![Mean costs of CHOP versus R-CHOP (2003 euro) for treatment of diffuse... | Download Scientific Diagram Mean costs of CHOP versus R-CHOP (2003 euro) for treatment of diffuse... | Download Scientific Diagram](https://www.researchgate.net/publication/227690315/figure/tbl3/AS:892267187429376@1589744483891/Mean-costs-of-CHOP-versus-R-CHOP-2003-euro-for-treatment-of-diffuse-large-B-cell.png)
Mean costs of CHOP versus R-CHOP (2003 euro) for treatment of diffuse... | Download Scientific Diagram
![Making an Informed Treatment Choice for Aggressive Non-Hodgkin Lymphoma: The R-CHOP Regimen versus EPOCH-R Making an Informed Treatment Choice for Aggressive Non-Hodgkin Lymphoma: The R-CHOP Regimen versus EPOCH-R](https://jhoponline.com/images/jhop/2016/Dec_2016/JHOP-2016-12-treatment-table1.png)
Making an Informed Treatment Choice for Aggressive Non-Hodgkin Lymphoma: The R-CHOP Regimen versus EPOCH-R
![Treatment With Four Cycles of R-CHOP Is Non-Inferior to Six Cycles in Some Aggressive B-Cell Non-Hodgkin Lymphomas Treatment With Four Cycles of R-CHOP Is Non-Inferior to Six Cycles in Some Aggressive B-Cell Non-Hodgkin Lymphomas](https://apps.hematology.org/images/acn/2020/02/acn_6.4_lit_scan_table.jpg)
Treatment With Four Cycles of R-CHOP Is Non-Inferior to Six Cycles in Some Aggressive B-Cell Non-Hodgkin Lymphomas
![Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy](https://www.frontiersin.org/files/Articles/359740/fonc-08-00163-HTML/image_m/fonc-08-00163-g001.jpg)
Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy
![Medicina | Free Full-Text | Hormonal Changes after R-CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Prospective Study Medicina | Free Full-Text | Hormonal Changes after R-CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Prospective Study](https://pub.mdpi-res.com/medicina/medicina-58-00710/article_deploy/html/images/medicina-58-00710-g001.png?1653562797)
Medicina | Free Full-Text | Hormonal Changes after R-CHOP Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma: A Prospective Study
![R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study - The Lancet Haematology R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study - The Lancet Haematology](https://www.thelancet.com/cms/attachment/2119050227/2088518350/gr1.gif)
R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study - The Lancet Haematology
![Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone ( CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis - The Lancet Haematology Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone ( CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis - The Lancet Haematology](https://www.thelancet.com/cms/attachment/c0e30a78-9723-45dd-bb6e-2378a9da26ed/gr1.gif)
Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone ( CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis - The Lancet Haematology
![Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP - ScienceDirect Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0006497121003141-grabsf1.jpg)
Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP - ScienceDirect
![Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large ... Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large ...](https://ars.els-cdn.com/content/image/1-s2.0-S0959804916000885-fx1.jpg)
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large ...
![Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study | Blood Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study | Blood](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41408-021-00542-z/MediaObjects/41408_2021_542_Fig1_HTML.png)
Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study | Blood
![Making an Informed Treatment Choice for Aggressive Non-Hodgkin Lymphoma: The R-CHOP Regimen versus EPOCH-R Making an Informed Treatment Choice for Aggressive Non-Hodgkin Lymphoma: The R-CHOP Regimen versus EPOCH-R](https://jhoponline.com/images/jhop/2016/Dec_2016/JHOP-2016-12-treatment-table2.png)
Making an Informed Treatment Choice for Aggressive Non-Hodgkin Lymphoma: The R-CHOP Regimen versus EPOCH-R
![Cancers | Free Full-Text | Late Neurological and Cognitive Sequelae and Long -Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi Cancers | Free Full-Text | Late Neurological and Cognitive Sequelae and Long -Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi](https://www.mdpi.com/cancers/cancers-13-03401/article_deploy/html/images/cancers-13-03401-g004.png)
Cancers | Free Full-Text | Late Neurological and Cognitive Sequelae and Long -Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi
![IJMS | Free Full-Text | Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy IJMS | Free Full-Text | Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy](https://www.mdpi.com/ijms/ijms-23-03368/article_deploy/html/images/ijms-23-03368-g001.png)
IJMS | Free Full-Text | Effects of B-Cell Lymphoma on the Immune System and Immune Recovery after Treatment: The Paradigm of Targeted Therapy
![Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study - The Lancet Haematology Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study - The Lancet Haematology](https://www.thelancet.com/cms/attachment/838a02b9-3645-4c11-9099-9e19b7a63d9f/gr1.gif)